[HTML][HTML] Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen) …
Purpose Several professional societies have published guidelines for the clinical interpretation
of somatic variants, which specifically address diagnostic, prognostic, and therapeutic …
of somatic variants, which specifically address diagnostic, prognostic, and therapeutic …
Optical genome mapping in acute myeloid leukemia: a multicenter evaluation
…, C Cujar, R Kolhe, K Kroeger, B Pitel… - Blood …, 2023 - ashpublications.org
Detection of hallmark genomic aberrations in acute myeloid leukemia (AML) is essential for
diagnostic subtyping, prognosis, and patient management. However, cytogenetic/…
diagnostic subtyping, prognosis, and patient management. However, cytogenetic/…
[HTML][HTML] A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
…, J McMurry, S Patterson, C del Vecchio Fitz, BA Pitel… - Nature …, 2020 - nature.com
Precision oncology relies on accurate discovery and interpretation of genomic variants,
enabling individualized diagnosis, prognosis and therapy selection. We found that six prominent …
enabling individualized diagnosis, prognosis and therapy selection. We found that six prominent …
SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq)
…, FR Harris, TM Drucker, RM Zenka, BA Pitel… - Cancer Genetics, 2018 - Elsevier
Highlights • Comparison of junctions reported by mate-pair sequencing with SVAtools,
karyotype, FISH and CMA. • Breakpoint resolution by mate-pair sequencing using SVAtools is …
karyotype, FISH and CMA. • Breakpoint resolution by mate-pair sequencing using SVAtools is …
Characterization of unusual iAMP21 B‐lymphoblastic leukemia (iAMP21‐ALL) from the Mayo Clinic and Children's Oncology Group
…, CM Williamson, BA Pitel… - Genes …, 2022 - Wiley Online Library
Acute lymphoblastic leukemia (B‐ALL) with intrachromosomal amplification of chromosome
21 (iAMP21‐ALL) represents a recurrent high‐risk cytogenetic abnormality and accurate …
21 (iAMP21‐ALL) represents a recurrent high‐risk cytogenetic abnormality and accurate …
Collaborative, multidisciplinary evaluation of cancer variants through virtual molecular tumor boards informs local clinical practices
PURPOSE The cancer research community is constantly evolving to better understand
tumor biology, disease etiology, risk stratification, and pathways to novel treatments. Yet the …
tumor biology, disease etiology, risk stratification, and pathways to novel treatments. Yet the …
Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia
U Aypar, SA Smoley, BA Pitel… - European journal of …, 2019 - Wiley Online Library
Objective Acute myeloid leukemia (AML) can be subtyped based on recurrent cytogenetic
and molecular genetic abnormalities with diagnostic and prognostic significance. Although …
and molecular genetic abnormalities with diagnostic and prognostic significance. Although …
RNA sequencing identifies a novel USP9X‐USP6 promoter swap gene fusion in a primary aneurysmal bone cyst
Primary aneurysmal bone cyst (ABC) is a benign multiloculated cystic lesion of bone that is
defined cytogenetically by USP6 gene rearrangements. Rearrangements involving USP6 are …
defined cytogenetically by USP6 gene rearrangements. Rearrangements involving USP6 are …
[HTML][HTML] Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma
J Smadbeck, JF Peterson, KE Pearce, BA Pitel… - Blood cancer …, 2019 - nature.com
Fluorescence in situ hybridization (FISH) is currently the gold-standard assay to detect recurrent
genomic abnormalities of prognostic significance in multiple myeloma (MM). Since most …
genomic abnormalities of prognostic significance in multiple myeloma (MM). Since most …
Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance
…, RS Ohgami, KE Pearce, BA Pitel… - Blood …, 2021 - ashpublications.org
The basis for acquired resistance to JAK inhibition in patients with JAK2-driven hematologic
malignancies is not well understood. We report a patient with a myeloproliferative neoplasm …
malignancies is not well understood. We report a patient with a myeloproliferative neoplasm …